Literature DB >> 34306351

Changes and significance of serum FGF21 in children with primary nephrotic syndrome and chronic renal failure.

Nian Wei1,2, Zhi-Qiang Guo1, Fang Yang1.   

Abstract

OBJECTIVE: The aim of the study was to investigate the changes and significance of serum fibroblast growth factor 21 (FGF21) in children with primary nephrotic syndrome (PNS) and chronic renal failure.
METHODS: Pediatric patients with active PNS and normal renal function (the nephrotic syndrome group), pediatric patients with chronic renal failure (the renal failure group), and children who had healthy physical examinations (the control group) were included. The serum levels of FGF21, total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) were measured by enzyme-linked immunosorbent assay (ELISA), and the serum albumin and 24 h urine protein were measured in the PNS group.
RESULTS: Compared with the normal control group, the level of serum FGF21 in the PNS group and the renal failure group increased significantly (P < 0.05). The TC, TG, HDL-C, and LDL-C levels increased significantly in the PNS group (P < 0.05). The levels of TG and HDL-C increased significantly in the renal failure group (P < 0.05). The levels of TC, HDL-C, and LDL-C in the renal failure group were lower than those in the PNS group (P < 0.05). There was no significant difference in TG level between the two groups (P > 0.05).
CONCLUSION: The level of serum FGF21 may be correlated with the occurrence and development of nephrosis in children. The higher the level of serum FGF21, the more serious the renal injury. AJTR
Copyright © 2021.

Entities:  

Keywords:  Primary nephrotic syndrome; children/kids; fibroblast growth factor 21; renal failure; serum lipid

Year:  2021        PMID: 34306351      PMCID: PMC8290640     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  13 in total

1.  Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.

Authors:  C H Lee; E Y L Hui; Y C Woo; C Y Yeung; W S Chow; M M A Yuen; C H Y Fong; A Xu; K S L Lam
Journal:  J Clin Endocrinol Metab       Date:  2015-01-27       Impact factor: 5.958

2.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

3.  Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome.

Authors:  G C Shearer; F T Stevenson; D N Atkinson; H Jones; I Staprans; G A Kaysen
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

4.  FGF-21 as a novel metabolic regulator.

Authors:  Alexei Kharitonenkov; Tatiyana L Shiyanova; Anja Koester; Amy M Ford; Radmila Micanovic; Elizabeth J Galbreath; George E Sandusky; Lisa J Hammond; Julie S Moyers; Rebecca A Owens; Jesper Gromada; Joseph T Brozinick; Eric D Hawkins; Victor J Wroblewski; De-Shan Li; Farrokh Mehrbod; S Richard Jaskunas; Armen B Shanafelt
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

5.  Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice.

Authors:  Charis L Johnson; Jacqueline Y Weston; Sami A Chadi; Elena N Fazio; Murray W Huff; Alexei Kharitonenkov; Anja Köester; Christopher L Pin
Journal:  Gastroenterology       Date:  2009-08-05       Impact factor: 22.682

Review 6.  Nephrotic syndrome in childhood.

Authors:  Allison A Eddy; Jordan M Symons
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

7.  FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity.

Authors:  Peter Arner; Amanda Pettersson; Pamela J Mitchell; James D Dunbar; Alexei Kharitonenkov; Mikael Rydén
Journal:  FEBS Lett       Date:  2008-05-05       Impact factor: 4.124

8.  Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.

Authors:  Peng Hu; Ling Lu; Bo Hu; Peng Fei Du
Journal:  Scand J Clin Lab Invest       Date:  2009       Impact factor: 1.713

9.  Serum levels of the adipokine FGF21 depend on renal function.

Authors:  Sebastian Stein; Anette Bachmann; Ulrike Lössner; Jürgen Kratzsch; Matthias Blüher; Michael Stumvoll; Mathias Fasshauer
Journal:  Diabetes Care       Date:  2008-10-07       Impact factor: 17.152

10.  Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation.

Authors:  Chi Zhang; Minglong Shao; Hong Yang; Liangmiao Chen; Lechu Yu; Weitao Cong; Haishan Tian; Fangfang Zhang; Peng Cheng; Litai Jin; Yi Tan; Xiaokun Li; Lu Cai; Xuemian Lu
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.